Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice - PubMed (original) (raw)
Comparative Study
. 2001 Jan 20;12(2):193-204.
doi: 10.1089/104303401750061258.
Affiliations
- PMID: 11177556
- DOI: 10.1089/104303401750061258
Comparative Study
Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice
E M Gordon et al. Hum Gene Ther. 2001.
Abstract
Targeting cytocidal vectors to tumors and associated vasculature in vivo is a long-standing goal of human gene therapy. In the present study, we demonstrated that intravenous infusion of a matrix (i.e., collagen)-targeted retroviral vector provided efficacious gene delivery of a cytocidal mutant cyclin G1 construct (designated Mx-dnG1) in human cancer xenografts in nude mice. A nontargeted CAE-dnG1 vector (p = 0.014), a control matrix-targeted vector bearing a marker gene (Mx-nBg; p = 0.004), and PBS served as controls (p = 0.001). Enhanced vector penetration and transduction of tumor nodules (35.7 +/- 1.4%, mean +/- SD) correlated with therapeutic efficacy without associated toxicity. Kaplan-Meier survival studies were conducted in mice treated with PBS placebo, the nontargeted CAE-dnG1 vector, and the matrix-targeted Mx-dnG1 vector. Using the Tarone log-rank test, the overall p value for comparing all three groups simultaneously was 0.003, with a trend that was significant to a level of 0.004, indicating that the probability of long-term control of tumor growth was significantly greater with the matrix-targeted Mx-dnG1 vector than with the nontargeted CAE-dnG1 vector or PBS placebo. The present study demonstrates that a matrix-targeted retroviral vector deployed by peripheral vein injection (1) accumulated in angiogenic tumor vasculature within 1 hr, (2) transduced tumor cells with high-level efficiency, and (3) enhanced therapeutic gene delivery and long-term efficacy without eliciting appreciable toxicity.
Similar articles
- Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct.
Gordon EM, Liu PX, Chen ZH, Liu L, Whitley MD, Gee C, Groshen S, Hinton DR, Beart RW, Hall FL. Gordon EM, et al. Cancer Res. 2000 Jul 1;60(13):3343-7. Cancer Res. 2000. PMID: 10910035 - Retroviral gene therapy vectors for prevention of excimer laser-induced corneal haze.
Behrens A, Gordon EM, Li L, Liu PX, Chen Z, Peng H, La Bree L, Anderson WF, Hall FL, McDonnell PJ. Behrens A, et al. Invest Ophthalmol Vis Sci. 2002 Apr;43(4):968-77. Invest Ophthalmol Vis Sci. 2002. PMID: 11923236 - Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice.
Chen DS, Zhu NL, Hung G, Skotzko MJ, Hinton DR, Tolo V, Hall FL, Anderson WF, Gordon EM. Chen DS, et al. Hum Gene Ther. 1997 Sep 20;8(14):1667-74. doi: 10.1089/hum.1997.8.14-1667. Hum Gene Ther. 1997. PMID: 9322869 - Technology evaluation: Rexin-G, Epeius Biotechnologies.
Morse M. Morse M. Curr Opin Mol Ther. 2005 Apr;7(2):164-9. Curr Opin Mol Ther. 2005. PMID: 15844625 Review. - The 'timely' development of Rexin-G: first targeted injectable gene vector (review).
Gordon EM, Hall FL. Gordon EM, et al. Int J Oncol. 2009 Aug;35(2):229-38. Int J Oncol. 2009. PMID: 19578735 Review.
Cited by
- Engineering targeted viral vectors for gene therapy.
Waehler R, Russell SJ, Curiel DT. Waehler R, et al. Nat Rev Genet. 2007 Aug;8(8):573-87. doi: 10.1038/nrg2141. Epub 2007 Jul 3. Nat Rev Genet. 2007. PMID: 17607305 Free PMC article. Review. - Reconstructing the immune system with lentiviral vectors.
Olbrich H, Slabik C, Stripecke R. Olbrich H, et al. Virus Genes. 2017 Oct;53(5):723-732. doi: 10.1007/s11262-017-1495-2. Epub 2017 Jul 25. Virus Genes. 2017. PMID: 28744797 Free PMC article. Review. - Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.
Ong HT, Trejo TR, Pham LD, Oberg AL, Russell SJ, Peng KW. Ong HT, et al. Mol Ther. 2009 Jun;17(6):1012-21. doi: 10.1038/mt.2009.39. Epub 2009 Mar 10. Mol Ther. 2009. PMID: 19277014 Free PMC article. - A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.
Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. Chawla SP, et al. Mol Ther Oncolytics. 2018 Dec 14;12:56-67. doi: 10.1016/j.omto.2018.12.005. eCollection 2019 Mar 29. Mol Ther Oncolytics. 2018. PMID: 30705966 Free PMC article. - Optimizing targeted gene delivery: chemical modification of viral vectors and synthesis of artificial virus vector systems.
Boeckle S, Wagner E. Boeckle S, et al. AAPS J. 2006;8(4):E731-42. doi: 10.1208/aapsj080483. AAPS J. 2006. PMID: 17285739 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical